Form 4: Zoetis Executive Keith Sarbaugh Reports Stock Option and Restricted Stock Unit Grants
SEC Form 4 Filing
Executive Vice President Keith Sarbaugh reports the acquisition of stock options and restricted stock units in Zoetis Inc.
Summary
- Keith Sarbaugh, an Executive Vice President at Zoetis Inc., filed a Form 4 detailing changes in beneficial ownership.
- The report includes the grant of 4,453 stock options with an exercise price of $156.64, vesting in three annual installments starting February 19, 2025, and expiring ten years from the grant date.
- Sarbaugh also received 1,143 restricted stock units (RSUs) that will vest in three annual installments beginning February 19, 2025.
- The report also details existing holdings of RSUs and stock options from previous grants.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. It reflects standard executive compensation practices, incentivizing performance and aligning interests with shareholders. There are no immediate negative implications.
Positives
- The grant of stock options and RSUs aligns the executive's interests with those of the shareholders.
- Vesting schedules incentivize continued service and performance.
Future Outlook
The vesting of the stock options and RSUs is contingent upon the reporting person's continued service.
Industry Context
Stock option and RSU grants are common practices in the pharmaceutical industry to incentivize and retain key executives.
Comparison to Industry Standards
- Zoetis's equity compensation practices are generally in line with those of other large pharmaceutical companies such as Merck, Eli Lilly, and Pfizer, which also utilize stock options and restricted stock units as part of their executive compensation packages.
- The vesting schedules, typically three years, are also standard in the industry to ensure long-term alignment with shareholder interests.
Stakeholder Impact
- Shareholders: The grants align executive interests with shareholder value creation.
- Employees: The grants contribute to the overall compensation structure and may influence employee morale.
Key Dates
| Date | Description |
|---|---|
| 03/31/2023 | Date of grant for existing RSUs and stock options. |
| 02/06/2024 | Date of grant for existing RSUs and stock options. |
| 02/19/2025 | Date of the reported transaction (grant of stock options and RSUs); also the first vesting date for the newly granted options and RSUs. |
| 02/21/2025 | Date of filing the Form 4. |
Keywords
Form 4, Zoetis, Stock Options, Restricted Stock Units, Executive Compensation, Beneficial Ownership, Equity Incentive Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.